Illumina, Inc. $ILMN Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH decreased its stake in Illumina, Inc. (NASDAQ:ILMN) by 23.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 167,869 shares of the life sciences company’s stock after selling 52,543 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.11% of Illumina worth $16,016,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ILMN. Rise Advisors LLC grew its position in shares of Illumina by 173.6% during the first quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 224 shares during the last quarter. Parkside Financial Bank & Trust grew its position in Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 115 shares during the last quarter. Cullen Frost Bankers Inc. acquired a new stake in shares of Illumina in the second quarter valued at approximately $41,000. NewSquare Capital LLC raised its holdings in shares of Illumina by 604.9% during the second quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock valued at $41,000 after buying an additional 369 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its position in shares of Illumina by 2,936.8% during the first quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock worth $46,000 after buying an additional 558 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ILMN. Daiwa Capital Markets lowered Illumina from an “outperform” rating to a “neutral” rating and set a $94.00 price target on the stock. in a report on Tuesday, August 12th. Stephens set a $110.00 price target on shares of Illumina and gave the stock an “overweight” rating in a research note on Monday, August 4th. TD Cowen boosted their target price on Illumina from $110.00 to $115.00 and gave the stock a “hold” rating in a report on Friday, October 31st. UBS Group boosted their price objective on Illumina from $110.00 to $120.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. Finally, Cowen reaffirmed a “hold” rating on shares of Illumina in a research note on Friday, October 31st. Five equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $115.00.

Insider Buying and Selling

In other news, Director Scott Gottlieb bought 500 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were bought at an average cost of $122.13 per share, with a total value of $61,065.00. Following the purchase, the director directly owned 12,523 shares in the company, valued at $1,529,433.99. This trade represents a 4.16% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.17% of the company’s stock.

Illumina Price Performance

NASDAQ ILMN opened at $121.97 on Wednesday. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $153.06. The company has a market cap of $18.64 billion, a PE ratio of 15.44, a PEG ratio of 2.34 and a beta of 1.42. The stock’s 50-day moving average price is $103.75 and its two-hundred day moving average price is $96.73.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.16 by $0.18. The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business’s revenue for the quarter was up .4% on a year-over-year basis. During the same period last year, the company posted $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.